Resultados: 5

Nucleic acid testing identifies high prevalence of blood borne viruses among approved blood donors in Mozambique

PLos ONE; 17 (4), 2022
Background: Although blood transfusion is an intervention that saves lives, it poses significant risks to the blood receivers, including the transmission of bloodborne pathogens. We aimed at determining the prevalence of Human Immunodeficiency Virus (HIV), Hepatitis B virus (HBV), and Hepatitis C virus (...

Stability of HIV-1 Nucleic Acids in cobas Plasma Separation Card for Viral Load Measurement

Am. j. clin. pathol; 158 (1), 2022
Objectives: Our study aimed to evaluate the stability of human immunodeficiency virus 1 (HIV-1) RNA on cobas plasma separation card (PSC) specimens for viral load (VL) testing after being exposed to varied temperatures and storage times. Methods: For this purpose, venous PSC specimens were collected and ...

Bat Astrovirus in Mozambique

Virol. j; 14 (104), 2018
Astroviruses (AstVs) are responsible for infection of a large diversity of mammalian and avian species, including bats, aquatic birds, livestock and humans. We investigated AstVs circulation in bats in Mozambique and Mayotte, a small island in the Comoros Archipelago located between east Africa and Madag...

Evaluation of the Whole-Blood Alere Q NAT Point-of-Care RNA Assay for HIV-1 Viral Load Monitoring in a Primary Health Care Setting in Mozambique

J. clin. microbiol; 54 (4), 2016
Viral load testing is the WHO-recommended monitoring assay for patients on HIV antiretroviral therapy (ART). Point-of-care (POC) assays may help improve access to viral load testing in resource-limited settings. We compared the performance of the Alere Q NAT POC viral load technology (Alere Technologies,...

Genetic analysis and natural polymorphisms in HIV-1 gp41 isolates from Maputo City, Mozambique

AIDS res. hum. retrovir; 30 (6), 2014
Enfuvirtide was the first fusion inhibitor approved by the Food and Drug Administration (FDA) in 2003 for HIV-1 infection in treatment-experienced patient. It is the first approved antiviral agent to attack the HIV life cycle in its early stages. For HIV fusion to occur, the HR1 and HR2 domains in the gp...